Phase I/2 Study of PX-866 and Docetaxel in Patients with Solid Tumors (PX-866-002)

PrintE-mail
Title Phase I/2 Study of PX-866 and Docetaxel in Patients with Solid Tumors (PX-866-002)
Contact DN
Principal Investigator Yujie Zhao, MD
Study Number 175510
Phase2
Summary

The purpose of the phase 2 part of the study is to find out whether PX-866 in combination with docetaxel is better than docetaxel alone at treating patients with locally advanced, recurrent, or metastatic non-small cell lung cancer or squamous cell cancer of the head and neck.

Eligibility See Clinical trials.gov link
For more information about the clinical study go to Clinicaltrial.Gov

Cancer Can't Win

More patients are being diagnosed with cancer every day.

Here at Roswell Park Cancer Institute, we must continue to do what we do best – to understand, prevent and cure cancer. Because if we don’t, cancer wins. And Cancer Can’t Win.

  • With more than 3,000 scientific, academic and medical minds – Cancer Can’t Win.
  • When we are leading an advanced genetic program and creating next generation cancer vaccines to prevent it – Cancer Can’t Win.
  • When we are starting 13 new companies to advance our discoveries and share them with the world – Cancer Can’t Win.

Learn more about why Cancer Can’t Win

close